Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zeria Pharmaceutical
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Subjects with unresectable locally advanced or metastatic pancreatic cancer

• KPS > 70%

• Life expectancy of at least 3 months

Exclusion Criteria:

• received previous chemotherapy for the current indication

• received previous radiotherapy for the current indication

• Currently receiving chemotherapy